Division of Gastroenterology, Indiana University, Indianapolis, Indiana.
Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.
Clin Gastroenterol Hepatol. 2019 Jan;17(2):345-352. doi: 10.1016/j.cgh.2018.09.029. Epub 2018 Sep 27.
Clostridium difficile infection (CDI) has become the leading cause of nosocomial infection in the United States with significant risk of both morbidity and mortality. While antimicrobial therapy forms the basis of treatment, there are several clinical scenarios in which antimicrobial therapy alone is insufficient. Evidence continues to show the safety and efficacy fecal microbiota transplantation (FMT) in recurrent and severe CDI. This review will outline FMT efficacy, safety, and indications and present practical advice for clinicians interested in best practices around delivery of FMT.
艰难梭菌感染(CDI)已成为美国医院感染的主要原因,具有较高的发病率和死亡率风险。虽然抗菌治疗是治疗的基础,但在某些临床情况下,仅使用抗菌治疗是不够的。有证据表明,粪便微生物群移植(FMT)在复发性和严重 CDI 中的安全性和有效性。本文将概述 FMT 的疗效、安全性和适应证,并为有兴趣了解 FMT 实施最佳实践的临床医生提供实用建议。